Author: Seward C1, Skolny M1, Brunelle C2, Asdourian M1, Salama L1, Taghian AG3
Affiliation: <sup>1</sup>Department of Radiation Oncology, Lymphedema Studies Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.
<sup>2</sup>Department of Physical and Occupational Therapy, Massachusetts General Hospital, Boston, Massachusetts.
<sup>3</sup>Department of Radiation Oncology, Lymphedema Studies Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts. ataghian@partners.org.
Conference/Journal: J Surg Oncol.
Date published: 2016 Oct
Other:
Volume ID: 114 , Issue ID: 5 , Pages: 537-542 , Special Notes: doi: 10.1002/jso.24365. Epub 2016 Jul 8. , Word Count: 103
As treatment for breast cancer improves and the threat of life-long chronic lymphedema becomes more prevalent, the need for effective screening tools emerges as crucial. This review was conducted using literature beginning in 1992 to analyze primary research testing the accuracy of bioimpedance spectroscopy as a diagnostic and early detection tool for breast cancer-related lymphedema. We concluded bioimpedance is an accurate diagnostic tool for pre-existent lymphedema, however, it has not been validated for early detection. J. Surg. Oncol. 2016;114:537-542. © 2016 Wiley Periodicals, Inc.
© 2016 Wiley Periodicals, Inc.
KEYWORDS: L-Dex; bioimpedance spectroscopy; breast cancer-related lymphedema (BCRL); early detection; multiple frequency bioimpedance analysis (MFBIA); perometry
PMID: 27393376 DOI: 10.1002/jso.24365